✦ LIBER ✦

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary syndromes

✍ Scribed by Matthias Schwenkglenks; John E. Brazier; Thomas D. Szucs; Keith A.A. Fox

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of bivalirudin versus

✍ Schwenkglenks, M.; Toward, T. J.; Plent, S.; Szucs, T. D.; Blackman, D. J.; Baum 📂 Article 📅 2012 🏛 BMJ 🌐 English ⚖ 322 KB

PCV116 COST-EFFECTIVENESS OF BIVALIRUDIN

✍ M Schwenkglenks; TD Szucs; JE Brazier; DJ Blackman; P Cyr; N Olchanski; GW Stone 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Comparison of Bivalirudin Versus Bivalir

✍ Dinesh Kumar; George Dangas; Roxana Mehran; Ajay Kirtane; Michel Bertrand; Ramin 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Treatment of non–ST-segment-elevation ac

✍ Matthew T Roe; David J Moliterno 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Early use of glycoprotein IIb/IIIa inhib

✍ Francis M Fesmire; Eric D Peterson; Matthew T Roe; James F Wojcik 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 236 KB

Trials of glycoprotein IIb-IIIa inhibito

✍ W. W. Parmley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB